Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.

Rosoux, Adeline;Pauwels, Patrick;Duplaquet, Fabrice;D'Haene, Nicky;Ocak, Sebahat;et.al.
(2016) Lung Cancer — Vol. 98, p. 118-121 (2016)

Files

RosouxALungCancer2016.pdf
  • Restricted Access
  • Adobe PDF
  • 528.45 KB
Request a copy

Details

Authors
Show more
Abstract
We report a case of crizotinib effectiveness in a heavily pretreated patient with a metastatic NSCLC initially considered IHC-positive and FISH-negative for ALK rearrangement. After repeated analyses of tumor samples, borderline ALK FISH-positivity (18.5% positive cells) was demonstrated.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Rosoux, A., Pauwels, P., Duplaquet, F., D’Haene, N., Weynand, B., Delos, M., Menon, R., Heukamp, L. C., Thunnissen, E., & Ocak, S. (2016). Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma. Lung Cancer, 98, 118-121. https://doi.org/10.1016/j.lungcan.2016.06.001 (Original work published 2016)